ArticleBMC cardiovascular disorders2026
Serum free fatty acids and progression of coronary artery calcification: sex specific findings from a large U.S. cohort study.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies evaluating the longitudinal relationship between plasma free fatty acids (FFAs) and subclinical atherosclerosis remain limited. We investigated the prospective association between serum FFA levels and the progression of coronary artery calcification (CAC) in a generally healthy, age-, sex-, and racially/ethnically diverse population.
methodsThis study utilized baseline data from the Multi-Ethnic Study of Atherosclerosis cohort, collected from 2000 to 2002, including 2988 women and 2696 men, with outcome data extending to 2012. CAC progression was defined as either the new onset of detectable CAC among participants with a baseline score of zero or a clinically meaningful increase in CAC severity among those with pre-existing CAC, based on established cut-offs. We employed Cox proportional hazards regression to calculate hazard ratios (HR) and 95% confidence intervals (95%CI) for the associations between FFAs and the CAC progression, stratified by sex. We evaluated potential non-linear relationships using restricted cubic splines.
resultsDuring the 9-year follow-up, we identified 1302 cases of CAC progression in women and 1480 cases in men. Serum FFAs were linearly associated with CAC progression in men, with a multivariable-adjusted HR of 1.41 (95% CI: 1.03-1.93) for each mmol/L increase in FFAs. Moreover, men in the highest relative to the lowest quintile of FFAs had a 20% higher risk (1.20; 1.02-1.43). Among women, we found evidence of a potential nonlinear association between FFAs and CAC progression, suggesting a threshold effect in their relationship (P non-linearity: 0.050). We observed no significant effect modification by age, body mass index, diabetes status, or hypertension in the relationship between FFAs and CAC progression.
conclusionsThis study highlights a significant association between FFAs and CAC progression in both men and women, though the nature of this association differs by gender.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.